论文部分内容阅读
乳腺癌是女性常见的恶性肿瘤之一,我国乳腺癌发病率呈上升趋势。目前乳腺癌的综合治疗使患者获得了较高的生存率。内分泌治疗是乳腺癌综合治疗中的重要措施之一,但其原、继发耐药是目前治疗中面临的主要问题。因此探讨内分泌治疗的耐药机制和寻找新的内分泌治疗靶点对于改善乳腺癌内分泌治疗失败患者的预后显得尤为重要。近年来许多研究表明,FGFR1在肿瘤发生、发展中起着重要作用。虽然目前研究显示,在部分乳腺癌中bFGR及受体FGFR1过度表达,但对乳腺癌组织中FGFR1表达情况的临床研究目前仍较少。本文就bFGF及FGFR1与乳腺癌内分泌治疗的意义作一综述。
Breast cancer is one of the common malignant tumors in women. The incidence of breast cancer in our country is on the rise. The current comprehensive treatment of breast cancer patients to obtain a higher survival rate. Endocrine therapy is one of the important measures in the comprehensive treatment of breast cancer, but its original and secondary drug resistance are the main problems in the current treatment. So to explore the mechanism of resistance to endocrine therapy and to find new targets for endocrine therapy for improving the prognosis of patients with failed breast cancer endocrine therapy is particularly important. In recent years, many studies have shown that FGFR1 plays an important role in tumorigenesis and development. Although studies have shown that bFGR and receptor FGFR1 are overexpressed in some breast cancers, there are still few clinical studies on the expression of FGFR1 in breast cancer tissues. This article reviews the significance of bFGF, FGFR1 and breast cancer endocrine therapy.